China-based Ab&B Bio-Tech announced on 27 July it passed the Hong Kong Stock Exchange (HKEX) listing hearing for its innovative vaccine portfolio, led by the country's first quadrivalent influenza subunit vaccine. The company plans to allocate 63.6% of IPO proceeds to develop core products, including Phase III trials for its human diploid cell rabies vaccine. Ab&B Bio reported RMB 260 million (USD 36 million) revenue in 2024 but recorded losses due to seasonal flu vaccine sales concentration in Q3. Founded in 2015, the company has raised RMB 994 million in pre-IPO funding with a post-money valuation of RMB 4.19 billion in 2021.

Chairman Youcai An controls 45.55% of shares through a concert party arrangement. Ab&B's pipeline includes 11 candidates such as pneumococcal and shingles vaccines. Its influenza vaccine launched in September 2023 achieved RMB 41 million (USD 5.7 million) sales in Q1 2025, with full-year revenue expected to surge during peak vaccination months.

According to PharmCube's NextBiopharm® database, Ab&B Bio's pipeline covers different vaccine modalities. Click here to request a free trial for NextBiopharm®.